The effects of vaginal bromocriptine and dienogest on women with adenomyosis: a clinical study

Abstract

Abstract Objective Adenomyosis occurs when endometrial glands and stroma develop in the myometrium, leading to symptoms such as pelvic pain and heavy menstrual bleeding. Method This randomized, double-blinded, controlled trial study was conducted on patients with adenomyosis referred to the Rasul-e-Akram Hospital. Group A received vaginal bromocriptine, and group B received dienogest. Transvaginal ultrasonography (TVS), visual analog scale (VAS), and pictorial blood loss assessment chart (PBLAC) evaluation were performed at the beginning and after 3, 6, and 9 months of the study. Result The mean blood visual chart 3 and 6 months after intervention in the bromocriptine group was significantly lower than the dienogest group (P < 0.001). The mean intensity of menstrual pain 3 months after intervention was significantly lower in the dienogest group compared to the bromocriptine group (P < 0.001). There was a significant improvement in TVS appearance in both groups at the 6-month follow-up. Conclusion Dienogest and bromocriptine both effectively reduced pain intensity, menstrual bleeding, and sonographic characteristics in patients with adenomyosis.

Keywords

• Adenomyosis
• Dienogest
• Bromocriptine
• Menstrual bleeding
• Pain